Anti Amyloid Kisunla denied as non-formulary by Humana?

Humana's specific coverage criteria for anti amyloid kisunla are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Kisunla as Non-Formulary

A non-formulary denial for Kisunla (donanemab) means the drug is either not included on Humana's standard drug list for the applicable plan, or it is placed at a tier that requires additional authorization — such as a specialty exception — before coverage is available. For novel anti-amyloid agents, formulary placement can lag behind FDA approval while the plan's pharmacy and therapeutics committee completes its review, or the drug may be placed at a non-preferred specialty tier with a formulary exception pathway.

## Why This Denial Is Appealable

For a drug with a specific FDA-approved indication and no therapeutically equivalent formulary alternative that works through the same mechanism, most plans are required to provide a formulary exception process. The absence of an equivalent covered alternative is a central pillar of the exception request. Humana's formulary exception policy will specify the criteria for an exception; your appeal demonstrates that those criteria are met.

## Your Federal Appeal Rights

• Formulary exception request / internal appeal: File a written formulary exception request with clinical documentation. Under ACA §2719 and ERISA §503, this is an adverse benefit determination subject to full-and-fair review.
• External review: If the internal exception and appeal are denied, independent external review is available under ACA §2719. File within approximately four months of the final internal denial.
• Expedited review: Available if waiting for standard review timelines would jeopardize the patient's health. Given Alzheimer's is progressive, document any clinical urgency explicitly.

## Documentation to Gather

1. Formulary alternative analysis — review Humana's current formulary for any covered agents used in early Alzheimer's disease. For each covered alternative, document why it is not clinically appropriate for this patient (different mechanism, prior failure, safety considerations per prescriber judgment, or not FDA-approved for this indication). 2. Diagnosis and eligibility confirmation — neurologist notes confirming early symptomatic Alzheimer's disease, amyloid PET or CSF biomarker results, cognitive staging documentation consistent with the FDA-approved population. 3. FDA prescribing label — confirm on-label use by attaching the label and identifying the exact indication and patient population. 4. Prescriber medical-necessity letter — from the treating neurologist or dementia specialist explaining why Kisunla is required and why no currently covered formulary alternative is clinically appropriate for this patient. 5. Humana's formulary exception criteria — obtain these from the plan documents or Humana's provider portal. Map each exception criterion to the clinical record and the absence of an appropriate formulary alternative.

## Criteria-Mapping Structure

Your appeal should lead with the formulary-alternative analysis — specifically, that no currently covered drug shares Kisunla's FDA-approved indication and mechanism for this patient's situation. Follow with the diagnosis and staging documentation, then the prescriber's clinical rationale. Address each of Humana's exception criteria directly in numbered form. Formulary exception denials for drugs with no covered therapeutic equivalent are among the more winnable appeal categories, particularly at external review.